Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Compensation Committee of Revance’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the
Revance’s global headquarters and experience center is located in
“Revance”, the Revance logo, and DAXXIFY are registered trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327126183/en/
Investors
jessica.serra@revance.com
or
New Street Investor Relations:
laurence@newstreetir.com
Media
cathryn.castaldo@revance.com
Source: